Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Dawnrays Pharmaceutical Holdings Ltd. ( (HK:2348) ) is now available.
Dawnrays Pharmaceutical (Holdings) Limited has scheduled a board meeting for 27 March 2026 to review and approve the audited annual results of the company and its subsidiaries for the financial year ended 31 December 2025. At the same meeting, the board will also consider whether to recommend a final dividend for shareholders, signalling an upcoming update on the group’s financial performance and potential cash returns.
The announcement also reconfirms the current composition of the board, which includes executive, non-executive and independent non-executive directors, underscoring the company’s adherence to corporate governance requirements. Investors will be watching the forthcoming results and any dividend proposal for indications of operational health and management’s confidence in the business outlook.
The most recent analyst rating on (HK:2348) stock is a Hold with a HK$1.50 price target. To see the full list of analyst forecasts on Dawnrays Pharmaceutical Holdings Ltd. stock, see the HK:2348 Stock Forecast page.
More about Dawnrays Pharmaceutical Holdings Ltd.
Dawnrays Pharmaceutical (Holdings) Limited is a Cayman Islands-incorporated pharmaceutical company listed in Hong Kong under stock code 2348. The group operates through subsidiaries and is engaged in the development, manufacturing and sale of pharmaceutical products, serving healthcare markets primarily from its base in the Greater China region.
Average Trading Volume: 195,703
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.73B
See more insights into 2348 stock on TipRanks’ Stock Analysis page.